A Phase 2 interventional study of Placebo and VTX3232 30 mg in Obesity, sponsored by Zomagen Biosciences Ltd.. Completed at 14 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Zomagen Biosciences Ltd. (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Obesity by Eli Lilly and Company — 31 open to participants now, 55 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 76th largest by enrollment of the 117 interventional ones that give a count, is one of 28 that started in 2025, is one of 22 in phase 2, and was the 65th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →31 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Brazil, China and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65 · Healthy volunteers
Eli Lilly and Company · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States
Ages 18–70
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 28 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 267 across the 117 interventional studies. Of the 61 that completed or were terminated, 29 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Zomagen Biosciences Ltd., one of the names counted as Eli Lilly and Company. Under that name alone:
Zomagen Biosciences Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
29 of the studies in Obesity by Eli Lilly and Company that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07232719Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | 2027-06 |
Add all 29 to your calendar (.ics) → With an account.
Among the 118 studies in Obesity by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in combination with semaglutide, or placebo in combination with semaglutide. The study consisted of a 30-day screening period, a 12-week double-blind treatment period, and a 30-day follow-up period. The maximum treatment duration was 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Receipt of the following medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo orally once daily for 12 weeks and were followed for 30 days after the last dose.
Drug: Placebo
Participants received VTX3232 30 milligrams (mg) orally once daily for 12 weeks and were followed for 30 days after the last dose.
Drug: VTX3232 30 mg
Participants received placebo orally once daily for 12 weeks and semaglutide administered subcutaneously once weekly for 12 weeks. Semaglutide doses were 0.25 mg during Weeks 0 - 3, 0.5 mg during Weeks 4 - 7 and 1.0 mg during Weeks 8 - 11. Participants were followed for 30 days after the last dose.
Drug: Placebo in combination with semaglutide
Participants received VTX3232 30 mg orally once daily for 12 weeks and semaglutide administered subcutaneously once weekly for 12 weeks. Semaglutide doses were 0.25 mg during Weeks 0 - 3, 0.5 mg during Weeks 4 - 7 and 1.0 mg during Weeks 8 - 11. Participants were followed for 30 days after the last dose.
Drug: VTX3232 30 mg in combination with semaglutide
Placebo
VTX3232 30 mg
Placebo in combination with semaglutide
Drug page: Semaglutide
VTX3232 30 mg in combination with semaglutide
Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)
A TEAE was defined as any adverse event that occurred after initiation of study treatment or any pre-existing adverse event that worsened in severity following initiation of study treatment.
Time frame: From the first dose of study treatment to Week 16
Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (Hs-CRP) Level
Time frame: From baseline to Week 12
| Milestone | Placebo | VTX3232 30 mg | Placebo + Semaglutide | VTX3232 30 mg + Semaglutide |
|---|---|---|---|---|
| Started | 43 | 44 | 43 | 45 |
| Received at least one dose of the study drug | 43 | 44 | 43 | 45 |
| Completed | 37 | 34 | 40 | 38 |
| Not completed | 6 | 10 | 3 | 7 |
| Withdrew: Lost to follow-up | 2 | 5 | 2 | 4 |
| Withdrew: Withdrawal by subject | 2 | 4 | 0 | 1 |
| Withdrew: Adverse event | 2 | 1 | 1 | 2 |
A TEAE was defined as any adverse event that occurred after initiation of study treatment or any pre-existing adverse event that worsened in severity following initiation of study treatment.
| Participants | Placebo | VTX3232 30 mg | Placebo + Semaglutide | VTX3232 30 mg + Semaglutide |
|---|---|---|---|---|
| Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) | 21 | 20 | 24 | 25 |
| Percent change | Placebo | VTX3232 30 mg | Placebo + Semaglutide | VTX3232 30 mg + Semaglutide |
|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (Hs-CRP) Level | 2.98 (-30.56 to 40.82) | -63.77 (-83.45 to -20.00) | -28.11 (-48.28 to 3.13) | -75.00 (-91.67 to -25.00) |
Collected over From baseline to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/43 (0%) | 0/43 (0%) | 13/43 (30.2%) |
| VTX3232 30 mg | 0/44 (0%) | 1/44 (2.3%) | 10/44 (22.7%) |
| Placebo + Semaglutide | 0/43 (0%) | 0/43 (0%) | 20/43 (46.5%) |
| VTX3232 30 mg + Semaglutide | 0/45 (0%) | 0/45 (0%) | 22/45 (48.9%) |
| Event | Placebo | VTX3232 30 mg | Placebo + Semaglutide | VTX3232 30 mg + Semaglutide |
|---|---|---|---|---|
| Major depressionPsychiatric disorders | 0/43 | 1/44 | 0/43 | 0/45 |
| Event | Placebo | VTX3232 30 mg | Placebo + Semaglutide | VTX3232 30 mg + Semaglutide |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/43 | 2/44 | 8/43 | 10/45 |
| ConstipationGastrointestinal disorders | 3/43 | 2/44 | 6/43 | 6/45 |
| Early satietyGeneral disorders | 1/43 | 2/44 | 6/43 | 5/45 |
| Decreased appetiteMetabolism and nutrition disorders | 2/43 | 1/44 | 6/43 | 6/45 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/43 | 0/44 | 3/43 | 5/45 |
| FatigueGeneral disorders | 2/43 | 1/44 | 4/43 | 5/45 |
| DiarrhoeaGastrointestinal disorders | 3/43 | 2/44 | 3/43 | 4/45 |
| VomitingGastrointestinal disorders | 0/43 | 1/44 | 3/43 | 1/45 |
| HeadacheNervous system disorders | 3/43 | 2/44 | 2/43 | 2/45 |
All randomized participants who received at least one dose of the study drug.
| Age, Continuous(years) | Placebo | VTX3232 30 mg | Placebo + Semaglutide | VTX3232 30 mg + Semaglutide | Total |
|---|---|---|---|---|---|
| Mean | 47.0 ± 13.49 | 45.9 ± 13.45 | 47.7 ± 13.44 | 49.7 ± 14.67 | 47.6 ± 13.74 |
| Sex: Female, Male(Participants) | Placebo | VTX3232 30 mg | Placebo + Semaglutide | VTX3232 30 mg + Semaglutide | Total |
|---|---|---|---|---|---|
| Female | 33 | 34 | 34 | 35 | 136 |
| Male | 10 | 10 | 9 | 10 | 39 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | VTX3232 30 mg | Placebo + Semaglutide | VTX3232 30 mg + Semaglutide | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 12 | 9 | 9 | 15 | 45 |
| Not Hispanic or Latino | 31 | 35 | 34 | 30 | 130 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | VTX3232 30 mg | Placebo + Semaglutide | VTX3232 30 mg + Semaglutide | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 2 | 1 | 4 |
| Asian | 2 | 1 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 11 | 11 | 11 | 15 | 48 |
| White | 29 | 31 | 30 | 29 | 119 |
| More than one race | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | VTX3232 30 mg | Placebo + Semaglutide | VTX3232 30 mg + Semaglutide | Total |
|---|---|---|---|---|---|
| United States | 43 | 44 | 43 | 45 | 175 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2025 to primary completion in Sep 2025, 8 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 8 months is below that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.